SIR1-365: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -88% 1 42 Improvement, Studies, Patients Relative Risk RCTs -88% 1 42 Late -88% 1 42 SIR1-365 for COVID-19 c19early.org December 2025 FavorsSIR1-365 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Qu (DB RCT) -88% 1.88 [0.39-8.90] no recov. 23 (n) 19 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Late treatment -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk All studies -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk 1 SIR1-365 COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors SIR1-365 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Qu (DB RCT) -88% 1.88 [0.39-8.90] no recov. 23 (n) 19 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Late treatment -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk All studies -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk 1 SIR1-365 COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Favors SIR1-365 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Qu (DB RCT) -88% 1.88 [0.39-8.90] no recov. 23 (n) 19 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Late treatment -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk All studies -88% 1.88 [0.39-8.90] 23 (n) 19 (n) 88% higher risk 1 SIR1-365 COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.44 Effect extraction pre-specified(most serious outcome) Favors SIR1-365 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Qu (DB RCT) -88% 1.88 [0.39-8.90] no recov. 23 (n) 19 (n) Improvement, RR [CI] Treatment Control SIR1-365 COVID-19 outcomes c19early.org December 2025 Favors SIR1-365 Favors control